TY -的T1 -临床仿真移动Telestroke系统的可用性测试(P3.104) JF -神经学乔-神经学六世- 88 - 16补充SP - P3.104盟Kaitlynne希思AU -布勒Mehndir首页atta AU -芯片Decker AU -罗伯·劳伦斯盟-邓普西?威特AU -丹同伴盟Tamara Broadnax AU -弗拉基米尔Lavrentyev AU -摩西·费尔德曼盟Jeneane亨利AU -杰森王盟-安德烈斯鲁伊斯盟Kevon Hekmatodoost AU - Kenichiro小野盟穆罕默德巴蒂AU -巴西Rahim盟凯伊斯Toqeer AU -杰米·里克斯盟Theandra但是AU - Baaba Blankson AU -杰米·希思盟帕米拉布朗盟Poanna Bennam AU -胡安Lu盟沃伦·费尔顿AU -约瑟夫Ornato盟Sherita查普曼Y1 - 2017/04/18 UR - //www.ez-admanager.com/content/88/16_Supplement/P3.104.abstract N2 -目的:理解感知的移动ambulance-based Telestroke系统和评价系统的可用性。背景:最近重点放在优化中风患者的院前护理和呼吁创新方法进一步提高中风患者的院前护理的范式。移动送往医院之前的telestroke提出了一个新颖的解决方案来改善中风诊断和减少治疗时间。设计/方法:救护车配备的移动远程医疗系统执行远程中风评估。脚本化的场景是由演员在运输和评估医生使用美国国立卫生研究院卒中量表(署)。运输期间获得的分数而独立的床边和原作署分数。参与者完成了系统可用性量表(SUS),美国国家航空航天局任务负荷指数,视听传播的质量规模和修改可接受性的技术调查完成后署评估。此外,面试进行评估用户的体验和感知。描述性分析用于所有调查。加权kappa在署协议用于比较分数。一个回归模型被用来进一步变化。Results: Ten scripted scenarios were simulated twice during the mobile transport and once at bedside. All simulations were completed except for one. NIHSS scores between mobile, bedside and original scripted scenarios revealed good agreement [weighted kappa=0.76 (95% CI: 0.63–0.9, p=0.63)]. There were no statistically significant differences in NIHSS scores between evaluations. The results were independent of stroke scenarios, physicians, and actors. Overall, 92% and 81% raters deemed video and audio quality as “good” or “excellent” (rating <3) respectively. The overall mean SUS score was 69.1 (13.3). Content analysis identified strengths, usability issues, and safety concerns. Overall users identified similar usability issues with the technology including: audibility, connectivity, equipment stability, and poor visibility.Conclusions: Our study shows the feasibility and capability of a mobile telestroke system to accurately assess actors simulating stroke patients during transport.Study Supported by: Virginia Commonwealth University (VCU) Dean’s Enhancement Award, VCU CTSA (UL1TR000058) from the National Center for Advancing Sciences, CCTR Endowment Fund of Virginia Commonwealth University (VCU)Disclosure: Dr. Heath has nothing to disclose. Dr. Mehndiratta has nothing to disclose. Dr. Decker has nothing to disclose. Dr. Lawrence has nothing to disclose. Dr. Whitt has nothing to disclose. Dr. Fellows has nothing to disclose. Dr. Broadnax has nothing to disclose. Dr. Lavrentyev has nothing to disclose. Dr. Feldman has nothing to disclose. Dr. Henry has nothing to disclose. Dr. Wong has nothing to disclose. Dr. Ruiz has nothing to disclose. Dr. Hekmatodoost has nothing to disclose. Dr. Ono has nothing to disclose. Dr. Bhatti has nothing to disclose. Dr. Rahim has nothing to disclose. Dr. Toqeer has nothing to disclose. Dr. Ricks has nothing to disclose. Dr. Madu has nothing to disclose. Dr. Blankson has nothing to disclose. Dr. Heath has nothing to disclose. Dr. Brown has nothing to disclose. Dr. Bennam has nothing to disclose. Dr. Lu has nothing to disclose. Dr. Felton has received compensation from Biogen Idec, Teva, Bristol-Myers Squibb, Serono, Sanofi-Aventis and Pfizer for speaking. Dr. Felton has received research support from the following organizations: NIH (WARCEF), Merck (MERCK), Novartis (ACCOMPLISH), Eli Lilly [amp] Centocor (AbESTT), NMT Medical (CLOSURE), Boehringer Ingelheim (PRoFESS), Ono Pharma USA (ONO), Biogen Idec (CHA). Dr. Ornato has nothing to disclose. Dr. Chapman has nothing to disclose. ER -